Abstract
Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients’ poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
Keywords: Antitubercular agents, review, tuberculosis, tubercular vaccines, tuberculosis diagnosis.
Infectious Disorders - Drug Targets
Title:Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Volume: 15 Issue: 1
Author(s): Mohamed Jawed Ahsan, Mohammad Yousuf Ansari, Sabina Yasmin, Surender Singh Jadav, Pradeep Kumar, Shiv Kumar Garg, Ajay Aseri and Habibullah Khalilullah
Affiliation:
Keywords: Antitubercular agents, review, tuberculosis, tubercular vaccines, tuberculosis diagnosis.
Abstract: Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients’ poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
Export Options
About this article
Cite this article as:
Jawed Ahsan Mohamed, Yousuf Ansari Mohammad, Yasmin Sabina, Jadav Surender Singh, Kumar Pradeep, Kumar Garg Shiv, Aseri Ajay and Khalilullah Habibullah, Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526514666140923153329
DOI https://dx.doi.org/10.2174/1871526514666140923153329 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano Particles: Emerging Warheads Against Bacterial Superbugs
Current Topics in Medicinal Chemistry The Chemical Dynamics of NO and Reactive Nitrogen Oxides: A Practical Guide
Current Molecular Medicine Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind...
Current Drug Metabolism Meet Our Editorial Board Member
Current Respiratory Medicine Reviews Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Monoterpenoid Geraniol Improves Anti-mycobacterial Drug Efficiency by Interfering with Lipidome and Virulence of Mycobacteria
Infectious Disorders - Drug Targets The Comparison of Pleural Fluid TNF-α and IL-10 Levels with ADA in Tuberculous Pleural Effusion
Current Medicinal Chemistry P2X7 1513 A>C Polymorphism Confers Increased Risk of Extrapulmonary Tuberculosis: A Meta-analysis of Case-Control Studies
Current Genomics Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application
Current Drug Research Reviews Microbial Efflux Pump Inhibition: Tactics and Strategies
Current Pharmaceutical Design Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery Imidazole and Pyrazole: Privileged Scaffolds for Anti-Infective Activity
Mini-Reviews in Organic Chemistry Analysis of Gene Logic Networks for Arabidopsis
Current Bioinformatics Recent Developments in Azole Compounds as Antitubercular Agent
Mini-Reviews in Organic Chemistry Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Current Discovery Progress of Some Emerging Anti-infective Chalcones: Highlights from 2016 to 2017
Current Drug Discovery Technologies Synthesis, Antitrypanosomal and Antimycobacterial Activities of Coumarin N-acylhydrazonic Derivatives
Medicinal Chemistry